Acquisition of a majority stake of Biofarma Group by Ardian

Mediobanca assisted Ardian in the acquisition of a majority stake in Biofarma Group for ~€1.1bn. Mediobanca acted also as Underwriter and Bookrunner of the relevant acquisition financing package.

Headquartered in Mereto di Tomba (Udine, Italy), Biofarma is the Italian and European leader in the development, manufacturing and packaging of food supplements, medical devices and cosmetics for third parties. The Group leverages on 4 manufacturing sites and 3 R&D laboratories in Italy, manufacturing over 2,000 products, serving over 500 clients and distributing its products in more than 40 countries. In 2021A, Biofarma generated PF Revenues of €240m and EBITDA for €53m (EBITDA margin of 22%).

On January 15th, 2022, Ardian has reached an agreement with Biofarma’s shareholders to acquire the Group for an implied valuation of ca. EV ~€1.1bn. The Scarpa family, being Biofarma’s founding family, will retain its current 30% stake in the group in partnership with Ardian while the current CEO, Mr. Maurizio Castorina, will continue to lead the company in its current role.

Ardian is a world-leading investment firm with $120bn of assets under management, +800 employees and 15 offices worldwide. The private equity is active across Europe, the Americas, Asia and Middle East and operates through multiple investment strategies
In the context of this transaction, Mediobanca acted as M&A Financial Advisor to Ardian. Furthermore Mediobanca, alongside other 2 primary financial institutions, acted as Underwriter and Bookrunner of the relevant acquisition financing package.

The deal is a testament to Mediobanca’s expertise and track record in the Pharmacetical and Nutraceutical industries in Italy while also strengthening the bank’s relationship with Ardian and the Scarpa family.